Latest news with #GoldmanSachsGlobalHealthcareConference
Yahoo
5 days ago
- Business
- Yahoo
TransMedics (TMDX) Continues to Scale Innovation in Organ Transplant Care
TransMedics Group Inc. (NASDAQ:TMDX) is one of the 10 best growth stocks to buy according to billionaires. The stock has had a tremendous year so far, with share price gains of 129%, leading other stocks in this list by a considerable margin, as none of the other stocks here have even reached 100%. In 2024, the company's revenue surged a robust 83%, and the street expects it to post a solid 31% growth in FY 2025. The company is also likely to experience significantly improved profitability, as consensus EPS forecasts a 77% growth this year and a 38% growth next year. A doctor performing a living donor kidney transplant in a hospital operating room, emphasizing the importance of medical advancements. On June 9, Canaccord Genuity analyst William Plovanic reaffirmed a Buy rating on TransMedics Group Inc. (NASDAQ:TMDX) with an unchanged price target of $129. This reaffirmation follows the company's June 9 presentation at the Goldman Sachs Global Healthcare Conference, where the company reaffirmed the strategy behind its industry-leading position in organ transplantation. Its execution continues to support a positive outlook, with management sharing tangible progress toward its long-term targets. At the centre of the story is the National OCS Program (NOP), which now drives nearly all company revenue, enabling TransMedics to offer a full-service, end-to-end transplant logistics and technology solution. This model has not only boosted transplant volumes but also established a critical advantage that competitors have yet to replicate. The company is targeting $1.2 billion in revenue and a 30% operating margin by 2028, driven by the expanded adoption of its Organ Care System and the upcoming next-generation platforms. Notably, its leadership in the DCD (donation after circulatory death) heart category, which now makes up about half of all U.S. heart donors, reflects its role in expanding the donor pool. TransMedics Group Inc. (NASDAQ:TMDX) is well-positioned to introduce new platforms for heart, lung, and kidney care in the coming years, including a Gen 3 system designed for greater portability and scalability. With strong clinical data and operational depth, the company appears well-positioned to hit its 10,000 annual transplants milestone by 2028 and continue growing from there. Management expects its kidney platform to launch by 2027 and aims to achieve 20,000 to 30,000 transplants over the next three to five years. TransMedics Group Inc. (NASDAQ:TMDX) is a commercial-stage medical technology company offering organ transplant therapy for patients with end-stage organ failure across multiple disease states. While we acknowledge the potential of TMDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
12-06-2025
- Business
- Yahoo
M&A to play ‘important role' at Teladoc: CEO
This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. Mergers and acquisitions should play an 'important role' in Teladoc's future business strategy, the virtual care firm's CEO said Wednesday. 'We're going to make investments not just for the short term, but things that we think are going to start to increase that [total addressable market], start to increase the scope and range of what we can do. And we think that's the right place to deploy our capital,' CEO Chuck Divita said at the Goldman Sachs Global Healthcare Conference. The telehealth company has already completed two acquisitions this year, scooping up preventive care firm Catapult Health in February and virtual mental health provider UpLift last month. Teladoc plans to be balanced on capital spending between investments within the firm — like spending on data and analytics and improving customer engagement with its suite of virtual care products — and external growth, including M&A, CFO Mala Murthy said Wednesday. Potential targets for M&A would focus on tuck-ins that could improve patient engagement, buys that would 'expand the aperture in terms of services' and international additions, Murthy said. Expanding the firm's reach in other countries has been a priority for the telehealth vendor. 'It's always going to be strong strategic rationale, and it has to make sense for us in terms of driving our top-line growth on a sustained basis,' Murthy said. 'That's essentially what we'd be looking for.' Teladoc has already made acquisitions under Divita's tenure as CEO, which began a year ago. Buying Catapult, which offers a virtual annual exam with an in-home diagnostic kit, should allow Teladoc to catch members' health conditions early and funnel them toward its other offerings, like chronic condition management programs, executives said earlier this year. Meanwhile, the UpLift deal aims to speed the company's ability to accept insurance coverage for care delivered by its direct-to-consumer mental health segment, BetterHelp. The unit has struggled recently, and its adjusted earnings before interest, taxes, depreciation and amortization was cut in half in the first quarter. Cost is one barrier to getting customers to subscribe to the service, an area where accepting insurance could help, management said. Recommended Reading Teladoc to acquire virtual care company Catapult Health for $65M Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11-06-2025
- Business
- Yahoo
Pfizer CEO Mentioned No Drug Price Commitments by Pfizer Inc. (PFE)
Pfizer Inc. (NYSE:PFE) is one of the best wide moat stocks to buy now. On June 9, Pfizer, along with other drug manufacturers, had a meeting with the Trump administration to talk about reducing US drug prices. However, Pfizer's chief executive, Albert Bourla, mentioned that no commitments have been agreed upon. President Trump ordered drugmakers last month to slash the prices of their medicines so they match what other countries are paying. As per this executive order, the government was to select 'Most Favored Nation' target prices in 30 days. The Department of Health and Human Services called for drugmakers in the United States to revise their prices to align with the lowest price paid by similar high-income countries. At the Goldman Sachs Global Healthcare Conference, Albert Bourla commented: 'I don't know what we will hear in 30 days,' Reiterating Pfizer's focus on high-level ideas, Bourla added: 'The administration already started series of meetings with companies. … The meetings were cordial, but they were not digging into the substance,' A medical technician wearing protective gloves and a mask mixing a biopharmaceutical solution. For now, it is unclear how the US government will bring down drug prices, and this policy will be hard to execute, as per analysts and legal professionals. A spokesperson commented that Health Secretary Robert F. Kennedy, Jr. would launch a system where American patients can directly buy their medicine from drug makers that sell to Americans at a 'Most-Favored-Nation' price. Pfizer's Bourla was hopeful that, due to American pressure on European nations to pay higher prices, the overall drug prices could rise. He stated that if America starts controlling prices, Pfizer Inc. (NYSE:PFE) could withhold drugs for government reimbursement in some countries if they do not increase prices there. He clarified: 'I don't think we will remove our products from the markets there – we will just remove them from reimbursement. We will leave them in open market.' Pfizer manufactures and sells biopharmaceutical products worldwide, catering to heart health, infectious diseases, migraines, immune disorders, and cancer. While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
11-06-2025
- Health
- Yahoo
Healthcare companies chase cures and capital in South Florida
Leaders of hundreds of public healthcare companies are in South Florida this week, talking up their innovations and financial performances to attract and impress investors at the Goldman Sachs Global Healthcare Conference. Consumers will find that nearly every disease or ailment they suffer from has a treatment in development, as big and small companies see opportunities in Americans' desire to live longer and pain-free. From new devices for sleep apnea to drugs for cancer, to creams for chronic itching and drops for improved eyesight, advances are underway that hold promise. Presenters like LENZ Therapeutics wowed the audience on Monday with product updates, such as an eyedrop that lasts all day and allows for close-up vision, which most people use reader glasses to achieve. The eye drops target a market of over 128 million people in the U.S. who need help with near vision. This year, new factors are affecting how quickly consumers can obtain a drug or device to improve or save their lives, according to company executives. The uncertainty in Washington, D.C., looms large. Policy turbulence, regulatory uncertainty, shakeups at health agencies and President Donald Trump's aggressive stance on drug pricing and tariffs factor into the future for the devices and treatments working their way toward the marketplace. Anti-Trump protests will unfold across South Florida this weekend. Here's what to expect Top RFK Jr. aide attacks US health system while running company that promotes wellness alternatives Hidden charges? Patients often face massive bills when Florida hospitals don't provide costs upfront Native Americans hurt by federal health cuts, despite RFK Jr.'s promises of protection Georgia's experience raises red flags for Medicaid work requirement moving through Congress 'This year, the biggest questions we are opening with for all of our companies is the policy calculus in Washington, D.C., and how that could play out across the healthcare sector,' said Asad Haider, Goldman Sachs' head of the healthcare business unit within Global Investment Research and the lead analyst for the U.S. pharmaceuticals sector. 'The starting point in all these presentations is give us the landscape on where things could go with respect to what's going on in Washington, D.C.' Over 200 top managerial teams attended the conference, representing every corner of the healthcare field, from major pharmaceutical companies to small biotech firms. The goal of the three-day conference was to provide institutional investors with insights into companies' business plans, data, and progress, particularly at a strategic mid-year point. Innovation hotspots this year include treatments for weight loss, with a focus on oral drugs replacing injectables and medications to help maintain a healthy weight. Another is oncology, immunology, and neuroscience with breakthroughs to detect diseases earlier and find new drug delivery methods. Several companies at the conference have formed partnerships with companies across the globe to access new markets, technologies, and expertise. China is emerging as a global leader in biotechnology, with numerous U.S. and European companies collaborating with or licensing technologies from Chinese companies. Summit Therapeutics, a Miami-based company, drew interest at the conference with its innovative cancer-fighting, bispecific antibody, ivonescimab, and its partnership with a Chinese laboratory. Ivonescimab has shown promise in previous trials in China and additional trials are underway combining the drug with chemotherapy to target non-small-cell lung cancer. 'We have over 22 or 23 different trials going on or completed or going to start,' said Maky Zangaheh, co-CEO of Summit Therapeutics. 'One element of that is a phase 3 trial that China and us are combining with over 3,000 patients enrolled, so we will have a good safety profile and efficacy profile in many different therapeutic areas. From a commercialization point of view, we are already in China and have two Chinese approvals, which is significant progress.' Doron Junger, of Sanvia Capital, a South Florida biotech investment firm, said he attended the conference looking to invest in companies developing innovations that could address large or niche markets in a more meaningful way. A few have caught his attention; however, he is cautious about those who tout therapies in their pipelines. 'More drug trials fail than succeed, and while there is a lot of innovation in this industry in areas of need like oncology and chronic diseases, even at a late stage, there is potential for a clinical trial to fail to show an advantage over a placebo group,' he said. 'Even if it does, that trial has to pass muster with the rigorous standards the FDA sets for approval.' On Monday, Arcturus Therapeutics of San Diego presented an update on a daily inhaled treatment for Cystic Fibrosis, which could be a breakthrough for the disease. Additionally, BioAge Labs CEO Kristen Fortney explained how her California company uses samples from a repository to study the biology of human aging and develop new therapies for obesity. Even after scrapping its lead obesity candidate due to liver toxicity, BioAge Labs is not shying away from the weight loss space and believes it can improve upon oral therapies now on the market, she said. 'More and more people are aging, and by definition, they are using more healthcare,' said Haider of Goldman Sachs. 'The aging population is going to need new drugs, better drugs, faster drugs for diabetes and cardiometabolics and oncology and all of these diseases that potentially could kill you. There will be innovation, but what are we willing to pay for that innovation?' Will regulations make it more difficult and/or costly for people to access the devices and drugs that can save their lives? Haider said drug pricing will be a key concern for both consumers and investors. 'Everyone is chasing big caps, big targets, but there will be winners and losers.' South Florida Sun Sentinel health reporter Cindy Goodman can be reached at cgoodman@
Yahoo
09-06-2025
- Business
- Yahoo
IBM all-time high, Universal Health falls, Topgolf Callaway rises
Market Domination co-host Yahoo Finance host Julie Hyman tracks today's top moving stocks and biggest market stories in this Market Minute. IBM (IBM) stock hit an all-time high and surpassed a $250 billion market cap. Universal Health Services (UHS) stock is under pressure after the company presented at the Goldman Sachs Global Healthcare Conference. Topgolf Callaway (MODG) stock is surging after a board member purchased $2.5 million in shares last week. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute. It's time for Yahoo! Finance's market minute. Shares of IBM hitting all-time highs on Monday. The stock also surpassing a market cap of $250 billion for the first time in the company's history. That move in the stock coming amid recent acquisitions, helping the company enter the high-growth software and services space. Universal Health Services under pressure following its presentation at the Goldman Sachs Global Healthcare Conference. The company's CFO, Steve Filton, saying labor shortages have impacted staffing and subacute facilities, according to Bloomberg. Filton also noted that the length of stay for patients is still higher than pre-COVID levels. Shares of Topgolf Callaway Brands surging in today's session, a securities filing showing that a board member purchased about $2.5 million worth of shares last week. The purchase signaling a boost of confidence in the tech-enabled golf company. And that's your Yahoo! Finance market minute. For more on what's trending on Yahoo! Finance, scan the QR code below. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
